NCT00550628View on ClinicalTrials.gov

Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Colorectal CancerNeoplasm of Uncertain Malignant Potential
Interventions
GENETIC

DNA methylation analysis

GENETIC

fluorescence in situ hybridization

GENETIC

gene expression analysis

GENETIC

polymerase chain reaction

GENETIC

protein expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

diagnostic laboratory biomarker analysis

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

PROCEDURE

biopsy

PROCEDURE

therapeutic conventional surgery

RADIATION

fludeoxyglucose F 18

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00550628 - Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer | Biotech Hunter | Biotech Hunter